Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1948 in Japanese patients with advanced solid tumors
NCT04094506Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2019
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP1948 in solid tumor (3 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicity up to 28 days, Adverse Events and 2 more. Started Oct 2019; status: completed.
02
Drugs
ASP1948
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04094506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094506.